Telmisartan
Brand: Micardis (US/EU) / Telma (IN) / Telsartan (IN) / Telsar (BD)
Antihypertensive
Angiotensin II receptor blocker (ARB)
Pharmacokinetics
| Half-life | 24 hours |
| Tmax | 1 h |
| Bioavailability | 40 % (approx) |
| Protein Binding | 99 % |
| Volume of Distribution | 0.15 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | no |
| Notes | Longest-acting ARB; PPAR-gamma partial agonist effect beneficial in insulin resistance and dyslipidemia. |
⚠️ Safety & Warnings
Severity: Moderate
Adverse Effects:
Dizziness, hyperkalemia, mild GI upset; rare angioedema
Contraindications:
Pregnancy, bilateral renal artery stenosis
Precautions:
Preferred in diabetes/metabolic syndrome due to PPAR-gamma effect; monitor potassium & renal function